# Extension Study of Participants From SPG302-ALS-001

> **NCT06903286** · PHASE2 · TERMINATED · sponsor: **Spinogenix** · enrollment: 16 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis (ALS)

## Interventions

- **DRUG:** SPG302

## Key facts

- **NCT ID:** NCT06903286
- **Lead sponsor:** Spinogenix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2025-05-29
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-08-31
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** patients treated through compassionate use program
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06903286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06903286, "Extension Study of Participants From SPG302-ALS-001". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06903286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*